323 related articles for article (PubMed ID: 25614274)
1. Denosumab for the treatment of osteoporosis.
Zaheer S; LeBoff M; Lewiecki EM
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):461-70. PubMed ID: 25614274
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
4. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
6. Denosumab in osteoporosis.
Diab DL; Watts NB
Expert Opin Drug Saf; 2014 Feb; 13(2):247-53. PubMed ID: 24289327
[TBL] [Abstract][Full Text] [Related]
7. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
8. [Denosumab - a new option in the treatment of osteoporosis].
Franek E
Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
[TBL] [Abstract][Full Text] [Related]
9. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a novel antiresorptive drug for osteoporosis.
Suresh E; Abrahamsen B
Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
[TBL] [Abstract][Full Text] [Related]
11. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
Kendler DL; Cosman F; Stad RK; Ferrari S
Adv Ther; 2022 Jan; 39(1):58-74. PubMed ID: 34762286
[TBL] [Abstract][Full Text] [Related]
13. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
14. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
Harris KB; Nealy KL; Jackson DJ; Thornton PL
J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
Iolascon G; Resmini G; Tarantino U
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
[TBL] [Abstract][Full Text] [Related]
17. [Denosumab for treatment of postmenopausal osteoporosis].
Syversen U; Halse JI; Geisler J; Eriksen EF
Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on denosumab in postmenopausal osteoporosis.
Moen MD; Keam SJ
BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
[TBL] [Abstract][Full Text] [Related]
19. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
[TBL] [Abstract][Full Text] [Related]
20. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
